Last updated on April 19, 2014 at 9:20 EDT

Medicago to Present at the Bloom Burton & Co. Healthcare Investment Conference

June 14, 2012

QUEBEC CITY, June 14, 2012 /PRNewswire/ – Medicago Inc. (TSX: MDG) (OTCQX: MDCGF), a biotechnology company focused
on developing highly effective and competitive vaccines based on
proprietary manufacturing technologies and Virus-Like Particles (VLPs),
today announced that Mr. Pierre Labbé, Vice-President and Chief
Financial Officer of Medicago, will be presenting at the Bloom Burton &
Co. Healthcare Investment Conference. The conference is being held at
the Toronto Board of Trade in Toronto, Ontario on June 21, 2012. Mr.
Labbé is scheduled to present at 3 pm ET.

About Bloom Burton & Co. and the Conference
Bloom Burton & Co. is Canada’s largest and most active
healthcare-specialized investment banking group. The team of healthcare
specialists merges scientific, medical, clinical, intellectual property
and commercial expertise with a strong understanding of the capital
markets, to advise and raise capital for private and public companies.
The Bloom Burton & Co. Healthcare Investor Conference brings together
U.S., Canadian and European investors who are interested in the latest
developments in the Canadian healthcare sector. Attendees will have an
opportunity to obtain corporate updates from the premier Canadian
public and private companies through presentations and break-out Q&A
sessions.  For more information, please visit www.bloomburton.com.

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel
vaccines and therapeutic proteins to address a broad range of
infectious diseases worldwide. The Company is committed to providing
highly effective and competitive vaccines and therapeutic proteins
based on its proprietary VLP and manufacturing technologies. Medicago
is a worldwide leader in the development of VLP vaccines using a
transient expression system which produces recombinant vaccine antigens
in plants. This technology has potential to offer more potent vaccines
with speed and cost advantages over competitive technologies, enabling
the development of a vaccine for testing in approximately one month
after the identification and reception of genetic sequences from a
pandemic strain. This production time frame has the potential to allow
vaccination of the population before the first wave of a pandemic, and
supply large volumes of vaccine antigens to the world market. Medicago
also intends to expand development into other areas such as biosimilars
and biodefense products where the benefits of our technologies can make
a significant difference. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements
This news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and uncertainties
associated with Medicago’s business and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “anticipate”, “believe”,
“plan”, “estimate”, “expect”, “intend”, and similar expressions to the
extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago’s current
expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from current
expectations, including the matters discussed under “Risk Factors and
Uncertainties” in Medicago’s Annual Information Form filed on March 29,
2012, with the regulatory authorities. Medicago assumes no obligation
to update the forward-looking statements, or to update the reasons why
actual results could differ from those reflected in the forward-looking

SOURCE Medicago Inc.

Source: PR Newswire